2026Sep
MRK Sep 2026 · Hold
Hold. At $150.33 on 2026-09-04, the shares stood above Fair value of $141.37, so the evidence does not support increasing exposure.Latest published research · analyzed 2026-09-08 · stale · sources stale
MRK · Archive
Read prior published editions, ratings, and price trends. Each row discloses its own analysis date.
USD 150.33
2026May
MRK May 2026 · Hold
Merck is a mature cash-generator currently heavily reliant on its blockbuster oncology drug Keytruda and the Gardasil vaccine franchise. While near-term cash flows and dividend safety are robust, the long-term investment thesis hinges on management's ability to successfully commercialize its pipeline of Antibody-Drug Conjugates (ADCs) and leverage M&A to offset the massive patent cliff approaching in 2028.Historical archived edition · analyzed 2026-05-08